Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall, Merck (MSD), Hikma, China Medical System - LARVOL DELTA

Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis. (PubMed, Acta Derm Venereol) - "Therefore, this study aims to evaluate the real-world CPR of adalimumab, ustekinumab, IL17- and IL23-inhibitors, incorporating both relative (Psoriasis Area and Severity Index; PASI75/90/100) and absolute (PASI ≤ 3/ ≤ 1) responder definitions and real-world dose adjustments. Tildrakizumab and bimekizumab were excluded due to limited data...Among biologics without biosimilar availability, the lowest CPRs were seen for brodalumab and guselkumab...The relevance of using real-world data, specifically with the use of absolute PASIs instead of relative PASIs, is shown in this study. Additionally, as price fluctuations have the biggest impact on cost-effectiveness, price transparency is essential to effectively guide physicians in selecting a cost-effective treatment strategy."

Clinical • Journal • Real-world evidence • Dermatology • Immunology • Psoriasis • IL17A

Off-Label Use of Tildrakizumab in Patients with Hidradenitis Suppurativa (CDA 2025) - "Currently, adalimumab and secukinumab are approved treatments for HS in Canada. While promising, these results are limited by the small sample size and lack of randomized controlled trials. Larger studies are needed to confirm its efficacy."

Clinical • Dermatology • Hidradenitis Suppurativa • Immunology • Pain • IL23A

Psoriasis vulgaris in patients with a recent history of neoplasia: safety of interleukin-23 inhibitors. A multicentre retrospective study. (PubMed, Clin Exp Dermatol) - "Our real-life experience is the largest study investigating the use of anti-IL-23 agents and the risk of cancer recurrence, progression and development in patients with a history of cancer. This study confirms their safety also in this cohort of patients."

Journal • Retrospective data • Dermatology • Immunology • Oncology • Psoriasis • IL23A

Biologics targeting IL-23 in moderate-to-severe psoriasis: lessons learned from real-world use. (PubMed, Expert Opin Biol Ther) - "Among these, IL23 inhibitors (guselkumab, risankizumab, and tildrakizumab), represent the most recent class of biologic drugs approved for the management of moderate-to-severe plaque psoriasis. Real-world evidence consistently confirms the strong efficacy, favorable safety profile, and long-term treatment durability of IL23 inhibitors across various patient subgroups, including those with comorbidities, prior biologic failures, and the involvement of difficult-to-treat areas. IL23 inhibitors have become key components of the therapeutic arsenal in psoriasis, and their performance in real-world settings continues to support their widespread adoption in clinical practice."

Journal • Real-world evidence • Review • Dermatology • Immunology • Inflammation • Psoriasis • IL23A

SOCIAL MEDIA PERSPECTIVES OF BIOLOGICS AND TARGETED THERAPY IN PSORIATIC ARTHRITIS (EULAR 2025) - "We then narrowed the search to specific treatments using the term ‘psoriatic arthritis’ coupled with ‘adalimumab’, ‘baricitinib’ ‘brodalumab’, ‘certolizumab’, ‘etanercept’, ‘guselkumab’, ‘infliximab’, ‘ixekizumab’, ‘risankizumab’, ‘secukinumab’, ‘tildrakizumab’, ‘tofacitinib’, ‘upadacitinib’, and ‘ustekinumab’ and as well as their respective brand names. Social media perceptions of biologics and targeted therapies are largely positive, however there is significant commentary on downsides including local/systemic adverse effects and lack/loss of efficacy. It is important that physicians in their consultations address these common patient concerns that may be perpetuated by social media."

Immunology • Inflammatory Arthritis • Pain • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

Tildrakizumab 200 mg: a step forward in psoriasis treatment with added metabolic benefits. (PubMed, J Dermatolog Treat) - "Increasing the tildrakizumab dose to 200 mg in partial responders with metabolic syndrome significantly improved both skin severity and metabolic profiles, lowering cholesterol, LDL, and glucose. These findings suggest a possible dose-dependent effect of tildrakizumab on metabolic parameters through enhanced IL-23 inhibition."

Journal • Cardiovascular • Dermatology • Immunology • Metabolic Disorders • Psoriasis • IL23A

Comprehensive Post-marketing safety analysis of Tildrakizumab: insights from the FDA adverse event Reporting system. (PubMed, Expert Opin Drug Saf) - "However, the FAERS database has limitations, including reporting bias, incomplete clinical information, and the inability to establish causality. These findings warrant further validation through prospective studies."

Adverse events • Journal • P4 data • Atrial Fibrillation • Basal Cell Carcinoma • Cardiovascular • Dermatology • Herpes Zoster • Immunology • Infectious Disease • Nephrology • Non-melanoma Skin Cancer • Oncology • Psoriasis • Varicella Zoster

Treatment of refractory pityriasis rubra pilaris with biologic therapy: a case series. (PubMed, Clin Exp Dermatol) - "Biologics demonstrated variable efficacy: significant responses were seen with secukinumab (n=3/4, 75%), tildrakizumab (n=2/7, 28.6%), ixekizumab (n=1/2, 50%), and risankizumab (n=1/1, 100%). Adalimumab yielded partial response for two patients (n=2/3, 66.7%)...Sequential biologic therapy demonstrated some benefit to non-responders. These findings highlight the need for standardised treatment outcome measures and further research in PRP treatment."

Journal • Dermatology

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis (clinicaltrials.gov) - P3 | N=99 | Completed | Sponsor: Sun Pharmaceutical Industries Limited | Active, not recruiting ➔ Completed

Trial completion • Dermatology • Immunology • Psoriasis

DMARDs and biologics are protective against alopecia areata in psoriasis patients (SID 2025) - "DMARDs analyzed included methotrexate, cyclosporine, apremilast. Biologic therapies included TNF-alpha inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol, golimumab), IL-17 inhibitors (brodalumab, ixekizumab, secukinumab, bimekizumab), and IL-12/23 and IL-23 inhibitors (ustekinumab, guselkumab, risankizumab, tildrakizumab)...IL-17 inhibitors (n=7, 670) were associated with a non-significant decrease in risk (RR: 0.909; 95% CI: 0.386-2.138). These findings demonstrate the protective nature of DMARDS and biologics, particularly TNF-alpha, IL-12/23, and IL-23 inhibitors, against AA in PsO patients, highlighting the need for further research into shared mechanisms of disease underlying PsO and AA."

Clinical • Alopecia • Dermatology • Genetic Disorders • Immunology • Inflammation • Obesity • Psoriasis • IL12A • IL17A • IL23A

Oral lichen planus treated with upadacitinib: A case series (SID 2025) - "Failed medications included hydroxychloroquine, tildrakizumab, and oral immunosuppressants (azathioprine, mycophenolate, cyclosporine). These cases suggest that upadacitinib may be a promising option in treating recalcitrant oral lichen planus. More studies need to be done to investigate the use of JAK inhibitors in treating oral lichen planus in larger controlled trials."

Clinical • Dermatology • Dermatopathology • Lichen Planus • Pain • IFNG

Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies. (PubMed, Dermatol Ther (Heidelb)) - "Tildrakizumab 200 mg effectively treated moderate-to-severe psoriasis across diverse patient subgroups. While higher weight and PASI were associated with slightly lower PASI100 rates, significant improvements were observed, supporting its role in difficult-to-treat patients."

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis

Systematic review of comparative studies on emerging psoriasis treatments: comparing biologics with biologics, small molecule inhibitors with small molecule inhibitors, and biologics with small molecule inhibitors. (PubMed, Inflammopharmacology) - "This systematic review highlights the enhanced efficacy of IL-17 and IL-23 inhibitors compared to TNF-α inhibitors, with IL-23-targeting agents demonstrating superior long-term disease control. Small molecule inhibitors, particularly Deucravacitinib, present a promising alternative as effective oral therapies. Although newer biologics offer improved treatment outcomes, further head-to-head trials comparing TYK2, JAK, and PDE4 inhibitors with IL-17 and IL-23 agents are warranted. These findings provide valuable insights to inform clinical decision-making and optimise Psoriasis management strategies."

Journal • Review • Candidiasis • Dermatology • Immunology • Infectious Disease • Psoriasis • IL17A • IL23A • TYK2

Age of Onset Matters: Tildrakizumab Response in Early vs Late-Onset Psoriasis. (PubMed, Br J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Psoriasis

Tildrakizumab Treatment Patterns in Adults With Moderate-to-Severe Plaque Psoriasis: A Retrospective Analysis From the Canadian Patient Support Program. (PubMed, Dermatol Ther (Heidelb)) - "Persistence and adherence to tildrakizumab were high through 52 weeks of treatment among patients with moderate-to-severe plaque psoriasis enrolled in the Canadian PSP."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis

Real-World Study of Tildrakizumab Survival in Psoriasis: Impact of Arthritis, Hypertension, and Prior Biologic Use. (PubMed, Life (Basel)) - "The most common reasons for treatment discontinuation were primary inefficacy and suboptimal response in patients with arthritis. Overall, tildrakizumab demonstrated robust survival outcomes in this patient population, though diminished persistence was observed in those with prior biologic use, comorbid arthritis, and hypertension."

Journal • Real-world evidence • Cardiovascular • Dermatology • Hypertension • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Pulmonary Arterial Hypertension • Rheumatology • Seronegative Spondyloarthropathies

Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe. (PubMed, J Dermatolog Treat) - "By targeting the interleukin (IL)-23p19 subunit of IL-23, the master cytokine of psoriasis pathogenesis, guselkumab, tildrakizumab, and risankizumab offer improved risk-benefit profiles. Altogether, these factors make these medicines ideal treatment options. Future research should focus on improving patient-reported outcomes, specifically addressing psychological and quality-of-life aspects, to further optimize psoriasis management."

Clinical • HEOR • Journal • Real-world evidence • Review • Dermatology • Immunology • Inflammation • Psoriasis • IL23A

Risk of adverse events of psoriasis treatment with biologic agents and new small molecules-BIOBADADERM Registry. (PubMed, J Eur Acad Dermatol Venereol) - "Our data support that, overall, the new biologic treatments have a superior safety profile in real-world practice compared to adalimumab and its biosimilars."

Adverse events • Journal • Dermatology • Immunology • Oncology • Psoriasis

A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment. (PubMed, Orphanet J Rare Dis) - "The application of immunomodulators in treating DCS was associated with satisfactory outcomes, although there is still a need to assess the long-term safety and effectiveness of these therapeutic agents in preventing disease progression and new flare-ups."

Journal • Review • Alopecia • Dermatology • Immunology • Oncology

Complete Resolution of Residual Psoriasis by Adding Tapinarof Cream to Tildrakizumab: A Case Report. (PubMed, J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Psoriasis

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. (clinicaltrials.gov) - P3 | N=192 | Recruiting | Sponsor: Sun Pharmaceutical Industries Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis

Efficacy and safety of tildrakizumab in patients with early- vs late-onset psoriasis. (PubMed, Br J Dermatol) - P3 | "Treatment with tildrakizumab was effective with no safety signals in both patient subgroups. Patients with late-onset psoriasis were more likely to achieve complete or near-complete clearance than were patients with early-onset psoriasis."

Journal • Dermatology • Immunology • Psoriasis

Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study (clinicaltrials.gov) - P=N/A | N=782 | Completed | Sponsor: Almirall, S.A. | Active, not recruiting ➔ Completed

HEOR • Real-world evidence • Trial completion • Dermatology • Immunology • Psoriasis

Almirall Q1 2025 Results (Businesswire) - "Ilumetri (tildrakizumab for the systemic treatment of moderate-to-severe psoriasis) delivered double digit growth in Q1 2025 (12.7% increase YoY) and delivered solid Net Sales of €55.1 MM despite growing competition in the psoriasis market and some quarterly phasing impacts. Wynzora continued to grow in its main markets and delivered total Net Sales of €7.7 MM representing a 22.2% increase vs Q1 2024. The strong double-digit growth performance of Klisyri in Q1 2025 (€6.9 MM +25.5% YoY) is aligned with expectations of its increasing market share in key regions and was further supported by the US large field launch following the approval of the label extension by the FDA in 2024."

Sales • Psoriasis

Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis. (PubMed, Dermatol Ther (Heidelb)) - "The investigated biologics demonstrated improved efficacy and QoL relative to placebo at week 28, with no increased risk of SAEs vs. placebo through week 16. At week 28, efficacy of tildrakizumab, risankizumab, and guselkumab was comparable. Limitations include lack of placebo comparators after week 12 or 16, which could affect results."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis